A well-funded Baltimore startup whose spray cryotechnology flash-freezes unwanted or malignant tissues inside the body just raised a touch more capital.
According to a regulatory filing, CSA Medical just raised $2.9 million – on top of the $55 million it’s raised to date. Before this, CSA Medical’s most recent fundraise was a $16 million Series C in 2013. Previous investors include Ascension Ventures, SV Life Sciences, Intersouth Partners, First Analysis, Rose Park Advisors and Blue Heron Capital.
CSA Medical’s spray cryotherapy devices have actually been FDA-cleared and on the market since 2007, in use for endoscopic ablation. But it recently developed a new system, called truFreeze, that delivers frigid liquid nitrogen through a small catheter to selectively destroy cells, while keeping the underlying collagen tissue structure preserved as a scaffold for heathy tissue to regrow. Here’s how it works:
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
